Literature DB >> 6231285

Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome.

T Mimori, M Hinterberger, I Pettersson, J A Steitz.   

Abstract

Autoantibodies directed against the U2 small nuclear ribonucleoprotein (snRNP) have been found in the serum of a patient with scleroderma-polymyositis overlap syndrome. This specificity, called anti-(U2)-RNP, is distinct from all previously described autoantibodies, including those that precipitate related snRNPs: anti-Sm antibodies, which react with the entire set of U1, U2, U4, U5, and U6 snRNPs, and anti-(U1)RNP antibodies, which recognize only U1 snRNPs. From HeLa cell extracts, anti-(U2)RNP immunoprecipitates predominantly one 32P-labeled RNA species, identified as U2 small nuclear RNA, and six [35S]methionine-labeled protein bands, A' (Mr = 32,000), B (Mr = 28,000), D (Mr = 16,000), E (Mr = 13,000), F (Mr = 12,000), and G (Mr = 11,000). Protein blot analysis reveals that the A' protein carries (U2)RNP antigenic determinant(s) and therefore represents a polypeptide unique to the U2 snRNP; the B protein associated with U2 snRNPs may also be unique. Like U1 and the other Sm snRNPs, U2 snRNPs occupy a nuclear, non-nucleolar location and are antigenically conserved from insects to man. An antibody specific for the U2 snRNP will be useful in deciphering the function of this particle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231285

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Viral transcription is necessary and sufficient for vesicular stomatitis virus to inhibit maturation of small nuclear ribonucleoproteins.

Authors:  D E Crone; J D Keene
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

2.  Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis.

Authors:  M Costa; J L Rodríguez-Sánchez; A J Czaja; C Gelpí
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  U1-U2 snRNPs interaction induced by an RNA complementary to the 5' end sequence of U1 snRNA.

Authors:  M C Daugeron; J Tazi; P Jeanteur; C Brunel; G Cathala
Journal:  Nucleic Acids Res       Date:  1992-07-25       Impact factor: 16.971

4.  Purification of the major UsnRNPs from broad bean nuclear extracts and characterization of their protein constituents.

Authors:  Z Pálfi; M Bach; F Solymosy; R Lührmann
Journal:  Nucleic Acids Res       Date:  1989-02-25       Impact factor: 16.971

5.  The U1 RNA-binding site of the U1 small nuclear ribonucleoprotein (snRNP)-associated A protein suggests a similarity with U2 snRNPs.

Authors:  C Lutz-Freyermuth; J D Keene; C Lutz-Reyermuth
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

6.  Proteolysis of splicing factors during rat and monkey cell fractionation.

Authors:  H La Branche; D Frappier; B Chabot
Journal:  Nucleic Acids Res       Date:  1991-08-25       Impact factor: 16.971

7.  Comparison of assay systems for detecting antibodies to nuclear ribonucleoproteins.

Authors:  P Merryman; P Louie
Journal:  J Clin Pathol       Date:  1991-08       Impact factor: 3.411

8.  Modifications of U2 snRNA are required for snRNP assembly and pre-mRNA splicing.

Authors:  Y T Yu; M D Shu; J A Steitz
Journal:  EMBO J       Date:  1998-10-01       Impact factor: 11.598

9.  A nuclear cap binding protein from HeLa cells.

Authors:  M Ohno; N Kataoka; Y Shimura
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

10.  Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases.

Authors:  B Combe; M Rucheton; H Graafland; V Lussiez; C Brunel; J Sany
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.